Therapeutic strategies for head and neck squamous cell carcinoma (HNSCC) have undergone a paradigm shift from chemotherapy, radiotherapy, and targeted therapy to immunotherapy, through the targeting of tumor cells and immune checkpoints (PD-1, PD-L1, and CTLA4). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.